The Irony of Humanization: Alemtuzumab, the First, But One of the Most Immunogenic, Humanized Monoclonal Antibodies

  title={The Irony of Humanization: Alemtuzumab, the First, But One of the Most Immunogenic, Humanized Monoclonal Antibodies},
  author={D. Baker and Liaqat Ali and G. Saxena and G. Pryce and M. Jones and K. Schmierer and G. Giovannoni and S. Gnanapavan and Kathleen C. Munger and L. Samkoff and A. Goodman and Angray S. Kang},
  journal={Frontiers in Immunology},
Alemtuzumab was designed to reduce the immunogenicity of the parent CD52-specific rat immunoglobulin. Although originally marketed for use in cancer (Mabcampath®), alemtuzumab is currently licensed and formulated for the treatment of relapsing multiple sclerosis (Lemtrada®). Perhaps due to its history as the first humanized antibody, the potential of immunogenicity of the molecule has been considered inconsequential, and anti-drug antibodies (ADA) responses were similarly reported as being… Expand
7 Citations
Detecting and predicting neutralization of alemtuzumab responses in MS
  • PDF
The Meaning of Immune Reconstitution after Alemtuzumab Therapy in Multiple Sclerosis
  • 3
  • Highly Influenced
  • PDF
[Updated recommendations of the Council of Experts on the use and safety of alemtuzumab (Lemtrada)].
The underpinning biology relating to multiple sclerosis disease modifying treatments during the COVID-19 pandemic
  • 25
Targeting Strategies for Enhancing Paclitaxel Specificity in Chemotherapy
  • Yuan Ma, Sifan Yu, +5 authors Ge Zhang
  • Frontiers in Cell and Developmental Biology
  • 2021


Characterisation of a Novel Anti-CD52 Antibody with Improved Efficacy and Reduced Immunogenicity
  • 21
  • PDF
A Novel Strategy To Reduce the Immunogenicity of Biological Therapies
  • 57
  • PDF
Impact of alemtuzumab treatment on the survival and function of human regulatory T cells in vitro
  • 52
Clinical pharmacology of alemtuzumab, an anti‐CD52 immunomodulator, in multiple sclerosis
  • 25
  • Highly Influential
Alemtuzumab depletion failure can occur in multiple sclerosis
  • 20